SCHEMBL1777932

SCHEMBL1777932

CNC(=O)CCc1c(-c2ccc(OS(=O)(=O)C(F)(F)F)cc2)[nH]c2nccnc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 19/20 0.49
GSK3B P49841 19/20 0.49
CDK1 P06493 18/20 0.49
CCNB2 O95067 17/20 0.49
CCNB1 P14635 17/20 0.49
CCNB3 Q8WWL7 17/20 0.49
CDK5 Q00535 12/20 0.49
CDK5R1 Q15078 11/20 0.49
CDK2 P24941 3/20 0.47
CCNE1 P24864 2/20 0.47
ZAP70 P43403 1/20 0.47
PTK2B Q14289 1/20 0.47
MAPK8 P45983 3/20 0.45
AURKA O14965 2/20 0.45
MAP4K4 O95819 2/20 0.45
PAK4 O96013 2/20 0.45
ABL1 P00519 2/20 0.45
FYN P06241 2/20 0.45
RET P07949 2/20 0.45
KDR P35968 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7253083 0.89 GSK3A (0.53) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL1777268 0.84 GSK3A (0.69) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL1777073 0.82 GSK3A (0.54) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL6852671 0.82 GSK3A (0.58) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL1777538 0.82 GSK3A (0.53) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL1779469 0.81 GSK3A (0.69) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL1778251 0.80 GSK3A (0.57) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL1777822 0.76 GSK3A (0.72) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL1777077 0.73 GSK3A (0.47) GSK3AGSK3BCDK1CCNB2CCNB1
SCHEMBL6846771 0.73 GSK3A (0.61) GSK3AGSK3BCDK1CCNB2CCNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943616-B2 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2011-05-17 US disclosed
EP-2233486-A1 Azaindoles Aventis Pharma Limited (GB) 2010-09-29 EP disclosed
US-20050267304-A1 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders AVENTIS PHARMACEUTICALS INC. (US) 2005-12-01 US disclosed
US-6897207-B2 Azaindoles AVENTIS PHARMACEUTICALS INC. (US) 2005-05-24 US disclosed
US-20040053931-A1 Azaindoles AVENTIS PHARMACEUTICALS INC. 2004-03-18 US disclosed
EP-1397360-A1 AZAINDOLES Aventis Pharma Limited (GB) 2004-03-17 EP disclosed
WO-2003000688-A1 AZAINDOLES AVENTIS PHARMA LIMITED (GB) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053931-A1 Azaindoles CDKN1A, CDK7, CDK2 GSK3A 456/4885GSK3B 409/4885CDK1 5/4885
US-20050267304-A1 Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders MAP3K20, MAP3K12, MAP3K19 GSK3A 176/4885GSK3B 187/4885CDK1 37/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.